Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Odyssey Therapeutics, Inc. ( ODTX ) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:45 AM EDT Company Participants Gary Glick - Founder, President, CEO & Director Presentation Unknown Analyst Good morning, everybody, and welcome to the Morgan Stanley Healthcare Conference. Very pleased to have on the stage Gary Glick, CEO of Odyssey Therapeutics. Before I kick off, just a few important notes. Please see the Morgan Stanley research disclosure website, www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. I was very concerned about finding this disclosure language. And now that that's out of the way, we can kick it off. Question-and-Answer Session Unknown Analyst So perfect. Gary, great to have you. Actually, I think this is the first time we're hosting you as a public company CEO at the Morgan Stanley Healthcare Conference. You've had a long history in both biotech and academia before you moved on to the private side. Can you give the audience just a little bit of background on what led to you founding Odyssey? And what was the sort of gap either from a scientific or medical standpoint that you were looking to fill and are looking to fill? Gary Glick Founder, President, CEO & Director Well, first, good morning, and thank you for the introduction. Good to see you again. So I've been working in inflammation and autoimmunity, I think, since 1990 when I started my faculty position and over the course of a number of different companies. And I've watched the sort of the space evolve over, I guess, close to 40 years now. And one of -- despite the fact that there's been, I think, advances across the field in making immunomodulators for a variety of different conditions, one of the things that really is still standing out for patients, the ability to treat large numbers of patients, put